Literature DB >> 32377247

WHICH FACTORS ARE ASSOCIATED WITH MALIGNANCY IN THYROID NODULES CLASSIFIED AS BETHESDA CATEGORY 3 (AUS/FLUS) AND HOW DO THEY INFLUENCE THE PATIENT'S MANAGEMENT?

C Kaya1, E Bozkurt2, D Türkyılmaz Mut3, M Mihmanli1, M Uludağ1.   

Abstract

BACKGROUND: Thyroid nodules are a common pathology worldwide. Fine needle aspiration biopsy (FNAB) is an important diagnostic method for the investigation of malignancy in thyroid nodules. However, according to the Bethesda System used to classify the results, patients with atypia of undetermined significance/follicular lesion of undetermined significance (AUS / FLUS) may not be classified as benign or malignant. Therefore, it may be necessary to determine some clinical risk factors to apply the best treatment in these patients. AIM: To determine the factors that increase the risk of malignancy in this patient group.
METHODS: A retrospective study including 138 patients with an FNAB categorized as AUS/FLUS and operated between June 2015-September 2018. Demographical, Laboratory (TSH) and Ultrasound variables (number, size and characteristics of nodules) of the patients were compared among postoperative histopathological results.
RESULTS: Hypo-echoic structure, microcalcification and irregular margin of the nodules were detected to be associated with malignancy in patients with FNAB results of AUS/FLUS (p <0.001).
CONCLUSION: We suggest that surgical treatment should be considered if the patients have nodules with the hypo-echoic structure, microcalcification and irregular margin with an FNAB histopathological result of AUS / FLUS. ©by Acta Endocrinologica Foundation.

Entities:  

Keywords:  Atypia of undetermined significance/follicular lesion of undetermined significance; Fine needle aspiration biopsy; Malignancy; Thyroid nodule

Year:  2019        PMID: 32377247      PMCID: PMC7200114          DOI: 10.4183/aeb.2019.491

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  24 in total

1.  Thyroid nodules with Bethesda system III cytology: can ultrasonography guide the next step?

Authors:  Hye Mi Gweon; Eun Ju Son; Ji Hyun Youk; Jeong-Ah Kim
Journal:  Ann Surg Oncol       Date:  2013-05-23       Impact factor: 5.344

2.  Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach?

Authors:  Paul A VanderLaan; Ellen Marqusee; Jeffrey F Krane
Journal:  Am J Clin Pathol       Date:  2011-05       Impact factor: 2.493

3.  Cytology-Ultrasonography Risk-Stratification Scoring System Based on Fine-Needle Aspiration Cytology and the Korean-Thyroid Imaging Reporting and Data System.

Authors:  Min Ji Hong; Dong Gyu Na; Jung Hwan Baek; Jin Yong Sung; Ji-Hoon Kim
Journal:  Thyroid       Date:  2017-05-19       Impact factor: 6.568

4.  Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.

Authors:  Enrico Papini; Rinaldo Guglielmi; Antonio Bianchini; Anna Crescenzi; Silvia Taccogna; Francesco Nardi; Claudio Panunzi; Roberta Rinaldi; Vincenzo Toscano; Claudio M Pacella
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

5.  The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference.

Authors:  Ritu Nayar; Marina Ivanovic
Journal:  Cancer       Date:  2009-06-25       Impact factor: 6.860

6.  Hemithyroidectomy: the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm.

Authors:  Sam M Wiseman; Christopher Baliski; Robert Irvine; Donald Anderson; Graeme Wilkins; Douglas Filipenko; Hongbin Zhang; Sam Bugis
Journal:  Ann Surg Oncol       Date:  2006-01-30       Impact factor: 5.344

7.  Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid?

Authors:  Rebecca S Sippel; Dina M Elaraj; Elham Khanafshar; Electron Kebebew; Quan-Yang Duh; Orlo H Clark
Journal:  Surgery       Date:  2007-10-26       Impact factor: 3.982

8.  Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).

Authors:  Allen S Ho; Evan E Sarti; Kunal S Jain; Hangjun Wang; Iain J Nixon; Ashok R Shaha; Jatin P Shah; Dennis H Kraus; Ronald Ghossein; Stephanie A Fish; Richard J Wong; Oscar Lin; Luc G T Morris
Journal:  Thyroid       Date:  2014-03-10       Impact factor: 6.568

9.  Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS).

Authors:  B Kuru; A Atmaca; I A Tarim; M Kefeli; K Topgul; S Yoruker; M Elmali; M Danaci
Journal:  Eur J Surg Oncol       Date:  2015-10-19       Impact factor: 4.424

10.  Malignancy Risk and Related Factors of Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance in Thyroid Fine Needle Aspiration.

Authors:  So-Hyeon Hong; Hyejin Lee; Min-Sun Cho; Jee Eun Lee; Yeon-Ah Sung; Young Sun Hong
Journal:  Int J Endocrinol       Date:  2018-07-30       Impact factor: 3.257

View more
  3 in total

1.  IS REPEAT FNAB NECESSARY FOR THYROID NODULES WITH ND / UNS CYTOLOGY?

Authors:  R Uçak; D Türkyilmaz Mut; C Kaya; B Yilmaz Ozguven; F Kabukcuoglu; M Uludağ
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

2.  Hashimoto's Thyroiditis Does Not Influence the Malignancy Risk in Nodules of Category III in the Bethesda System.

Authors:  Dorota Słowińska-Klencka; Bożena Popowicz; Mariusz Klencki
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

3.  Assessment of Preoperative TSH Serum Level and Thyroid Cancer Occurrence in Patients with AUS/FLUS Thyroid Nodule Diagnosis.

Authors:  Krzysztof Kaliszewski; Dorota Diakowska; Marta Rzeszutko; Łukasz Nowak; Beata Wojtczak; Krzysztof Sutkowski; Maksymilian Ludwig; Bartłomiej Ludwig; Agnieszka Mikuła; Maria Greniuk; Urszula Tokarczyk; Jerzy Rudnicki
Journal:  Biomedicines       Date:  2022-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.